Skip to main content
. 2020 Jan 7;19(3):1725–1732. doi: 10.3892/etm.2020.8430

Figure 2.

Figure 2.

Immunophenotype of ADSCs and BMSCs. The third passage cells were treated with FITC- or PE-labeled antibodies, followed by flow cytometry. Mesenchymal cell markers included CD49d, CD106, CD29 and HCAM. ADSCs, adipose tissue-derived stem cells; BMSCs, bone marrow-derived stem cells.